108 results about "Toxoid" patented technology

The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.

A pharmaceutical composition has a therapeutically effective amount of at least one of: a pharmaceutically active nasal peptide, its pharmaceutically acceptable salt and its peptidic fragment. The composition also contains an absorbefacient effective amount of THAM in a pharmaceutically acceptable, aqueous liquid diluent or carrier. The composition is provided in a convenient form for nasal administration. In one embodiment, the peptidic fragment may be selected physiologically active lymphokines and monokines, peptidic enzymes, proteic vaccines, peptidic toxoids and personalized proteins derived from genoma. In another embodiment, the peptidic fragment may be selected from the peptide hormones and hormone antagonists buserelin, desmopressin, vasopressin, angiotensin, felypressin, octreotide, somatropin, thyrotropin (TSH), somatostatin, gosereline, thryptorelin and insulin selected from the group consisting of cow and pig, synthetic and recombinant.

This invention provides botulinum antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The botulinum antitoxin is prepared by inoculating an animal with a monovalent botulinum toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven botulinum serotypes are then combined to produce a high titered heptavalent botulinum antitoxin composition.

A chimeric Shiga toxoid according to the invention contains an enzymatically-inactivated StxA subunit and a native StxB subunit. This hybrid Shiga toxoid induces the production of broadly cross-reactive species of antibodies against Shiga toxin following immunization. The StxA subunit is modified so that it is enzymatically inactive. The invention thus encompasses the Shiga toxoid or fragments thereof and the nucleic acid sequence of the Shiga toxoid or fragments thereof. The invention further encompasses the production of a Shiga toxoid, the production of antibodies using the Shiga toxoid and methods of productions, and an immunogenic composition containing the Shiga toxoid.

An immunogenic detoxified protein is provided which comprises the amino acid sequence of subunit A of an E. coli heat labile toxin (LT-A) or a fragment thereof in which at least amino acid Ala-72 of the A subunit is mutated, preferably by substitution with Arg. The toxoid is useful as vaccine against an enterotoxigenic strain of E. coli and is produced by recombinant DNA means by site-directed mutagenesis. It is also an effective adjuvant.

The invention provides an effective and environmentally friendly antibody protective agent and the methods of using it in immunological detection. The antibody protective agent helps antibody to maintain relatively high immunological activity at room temperature. Working electrodes coated with antibodies and the antibody protective agent are installed in immunological detection devices to enhance stability and accuracy of immunological detection. The antibody protective agent is effectively used in the detection of a variety of toxins, for example, aflatoxin, staphylococcal enterotoxin, algae toxin, and vomitoxin.

In the aim of practical utilization of a safe and effective transnasal/inactivated/mucosal vaccine and establishment of a technology for imparting capacity of producing both of IgA and IgG antibodies to a conventional inactivated vaccine, toxoid; allergen, or the like, a means for prevention and treatment of allergy, and the like, it is intended to provide an antigen-drug vehicle (AD vehicle) enabling transnasal, transmucosal, and transdermal administrations, an inactivated vaccine simultaneously inducing a mucosal immunity and humoral immunity by using the AD vehicle, a production method of the inactivated vaccine, an AD vehicle enabling a switch from induction of selective production of IgA antibody to induction of both of IgA and IgG antibodies, and a transnasal vaccine, a mucosal vaccine, a therapeutic/prophylactic agent for allergy, and the like using the AD vehicle.

The present invention relates to toxoid preparations comprising a non-disrupted and/or a non-denatured toxin associated with a particulate vector that minimizes or precludes said toxin from inflicting damage at an action site of said toxin. The present invention also relates to immunogenic compositions or vaccines comprising the toxoid preparations, and the methods of using the toxoid preparations, immunogenic compositions or vaccines.

The invention discloses an antibody for broad-spectrum detection of Bt Cry1 toxoids as well as a preparation method and application thereof. The antibody is generated by secretion of hybridoma cells with the collection number of CCTCC NO:C2015145, obtained after coupling antigen polypeptide SEQ ID NO.2 and carrier protein KLH and then immunizing Balb/c mice. The ratio of the antibody to OD450 of six kinds of Bt Cry1 toxoids to negative holes (PBS solution) is far larger than 2.1, and the antibody has relatively high titer, has a broad-spectrum detection effect on the Bt Cry1 toxoids and makes up the blank of the broad-spectrum detection field of the Bt Cry1 toxoids.

Acellular pertussis vaccines comprise purified toxin or toxoid thereof, filamentous haemagglutinin, pertactin and fimbrial agglutinogens formulated to confer protection to at least 70% of members of an at-risk population. The fimbrial agglutinogens may be prepared from a Bordetella strain, particularly a B. pertussis strain, by a multiple step procedure involving extraction of the fimbrial agglutinogens from cell paste and concentrating and purifying the extracted material.

The invention discloses a method for detecting the quality of south isatis root granules and belongs to the technical field of quality control of medicines. The method comprises the following steps of: preparing a comparison product solution; preparing a test article solution; performing gradient elution; making a standard fingerprint spectrum by using quinazoline dione as a reference peak; and controlling the quality of the fingerprint spectrum. In the method, quinazoline alkaloid is selected as an index for controlling the quality of south isatis root; the quinazoline alkaloid in south isatis root crude drugs has anti-toxoid and bacteriostatic actions; and the quinazoline alkaloid is relatively stable and small in content change in the south isatis root crude drugs, a preparation process and a preparation finished product. The standard fingerprint spectrum is established by using a high-efficiency liquid phase, the characteristics of active constituents of the south isatis root are taken as the principle things, and quantization parameters are obtained by using the fingerprint spectrum. The invention has the advantages that: the method is higher in accuracy and good in stabilityand repeatability; and the quality of a preparation can be more comprehensively and effectively controlled.

The invention discloses a device and a method for acquiring dioxin toxoid signals. The device comprises a photoelectric converter, a calculation amplifier, a pulse discriminator, a two divided-frequency counter, a control device and a digital-to-analog converter, wherein weak light emitted from living beings is converted into weak electric signals through the photoelectric converter, and subsequently amplified through the calculation amplifier and transmitted to the pulse discriminator; the pulse discriminator compares the signal voltage amplitude; when the pulse voltage amplitude exceeds a set threshold, a high level signal is output and is transmitted to the control unit through the two divided-frequency counter; the control unit transmits the set pulse voltage amplitude threshold to the pulse discriminator through the digital-to-analog converter; and the control unit is connected with an upper computer. The components are all supplied with power by a power supply management module. A working voltage of the photoelectric converter is supplied by a boost circuit. The invention further discloses an acquisition method based on the device. By utilizing the device and the method, the microsignal amplification is rapidly realized, background noise is effectively eliminated, and the measurement precision is improved.

The invention discloses feed active egg powder with nutrition, healthcare and growth promotion functions and a production method thereof, wherein the feed active egg powder with nutrition, healthcare and growth promotion functions is obtained by fully mixing weighed enterotoxin-resistant Escherichia coli tetravalent yolk antibody, C-type clostridium perfringens and beta toxoid-resistant divalent yolk antibody, rotavirus-resistant yolk antibody, transmissible gastroenteritis and epidemic diarrhea-resistant bigeminal yolk antibody, cholecystokinin/somatostatin-resistant double-fusion white and yolk antibody, lysozyme meringue powder, epidermal growth factor-containing meringue powder, common meringue powder and silica (antitackiness agent) for 60 to 100 seconds. The feed active egg powder with nutrition, healthcare and growth promotion functions provided by the invention has the beneficial effects of containing high-quality protein, fat and amino acid required for the growth and development of piglets, containing lysozyme, yolk antibody and epidermal growth factor for preventing disease, protecting health and promoting growth, and having four efficacies of enhancing the feed intake,accelerating the growth, boosting the immunity and controlling the diarrhea of the piglets before and after weaning.

The invention belongs to the technical field of plant inspection and quarantine, and specifically relates to a molecular identification method of trichothecene type-A toxins of fusarium. The molecular identification method of the invention is characterized by comprising the steps of: designing a pair of specific primers through Tril13 gene information aiming at the trichothecene type-A toxins; separating the fusarium which generates type-A toxins of the fusarium to obtain specific segments (the length is 470 bp) of T-2 toxins, wherein the specific segments cannot be amplified in the fusarium which does not generate the type-A toxins of the fusarium; and adopting PCR (Polymerase Chain Reaction) reaction and utilizing a product from agarose gel electrophoresis to determine whether one fusarium can generate T-2 toxins directly according to existence and size of a product segment. The molecular identification method disclosed by the invention can be used for detecting trichothecene type-A toxins of fusarium in grains, feed and food safety.

The invention discloses a cell antigen epitope peptide of A-typed botulism toxin B as core immune antigen, which is characterized by the following: protecting botulism toxin from infecting; identifying A-typed specific antibody of botulism toxin due to characteristic antigen mark; distinguishing A-type from other patterns in the serum; making the short peptide possess the same or similar function with full toxin antigen and recombinant toxin antigen without allergic reaction; overcoming the serum crossing problem among full toxin antigen or recombinant antigen; diagnosing the infection of botulism toxin to prepare new peptide vaccine; fitting for targeting and sieving botulism toxin resistant drug.